%0 Journal Article
%T Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
%A Ann G Schwartz
%A Antoinette Stroup
%A Brenda Y Hernandez
%A Carol Sweeney
%A Charles F Lynch
%A Charles Wiggins
%A Dave P Miller
%A Dennis Deapen
%A Frederick L Baehner
%A Kathleen Cronin
%A Kevin C Ward
%A Lloyd Mueller
%A Lynne Penberthy
%A Nadia Howlader
%A Nathan Gliner
%A Nicola Schussler
%A Rosemary Cress
%A Sally L Glaser
%A Stephen M Schwartz
%A Steven Shak
%A Thomas C Tucker
%A Valentina I Petkov
%A Will Howe
%A Xiao-Cheng Wu
%J Archive of "NPJ Breast Cancer".
%D 2016
%R 10.1038/npjbcancer.2016.17
%X The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results. The prespecified primary analysis cohort was 40每84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (N=38,568). Unadjusted 5-year BCSM were 0.4% (n=21,023; 95% confidence interval (CI), 0.3每0.6%), 1.4% (n=14,494; 95% CI, 1.1每1.7%), and 4.4% (n=3,051; 95% CI, 3.4每5.6%) for Recurrence Score <18, 18每30, and ˋ31 groups, respectively (P<0.001). In multivariable analysis adjusted for age, tumor size, grade, and race, the Recurrence Score result predicted BCSM (P<0.001). Among patients with node-positive disease (micrometastases and up to three positive nodes; N=4,691), 5-year BCSM (unadjusted) was 1.0% (n=2,694; 95% CI, 0.5每2.0%), 2.3% (n=1,669; 95% CI, 1.3每4.1%), and 14.3% (n=328; 95% CI, 8.4每23.8%) for Recurrence Score <18, 18每30, ˋ31 groups, respectively (P<0.001). Five-year BCSM by Recurrence Score group are reported for important patient subgroups, including age, race, tumor size, grade, and socioeconomic status. This SEER study represents the largest report of prospective BCSM outcomes based on Recurrence Score results for patients with HR+, HER2-negative, node-negative, or node-positive breast cancer, including subgroups often under-represented in clinical trials
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515329/